U.S. FDA Announces Plan To Address Antimicrobial Resistance

CIDRAP News: FDA plan focuses on antibiotic development, stewardship
“The U.S. Food and Drug Administration (FDA) [on Friday] announced a multipronged strategy to address antimicrobial resistance (AMR) that emphasizes new measures to spur development of antibiotics and alternative therapies, promote antibiotic stewardship in animal health, advance antibiotic resistance surveillance, and enhance regulatory science…” (Dall, 9/14).

Healio: FDA unveils new plan to kickstart drug development for resistant bacteria
“… ‘We cannot count on outracing drug resistance, but we can use stewardship and science to slow its pace and reduce its impact on human and animal health,’ FDA Commissioner Scott Gottlieb, M.D., said in a press conference. ‘To do so, we need an all-hands-on-deck approach to combating antimicrobial resistance in both human and veterinary settings’…” (Bortz, 9/14).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.